A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model

Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and targets multiple receptor tyrosine kinases. However, sorafenib only extends the average survival time by 3 months. This...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncol Lett
Hauptverfasser: Chuang, Hui-Yen, Tyan, Yeu-Sheng, Hwang, Jeng-Jong, Shih, Kuang-Chung, Lin, Wei-Chan
Format: Artigo
Sprache:Inglês
Veröffentlicht: D.A. Spandidos 2021
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7933744/
https://ncbi.nlm.nih.gov/pubmed/33692869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12598
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge